Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2022 Aim. The aim of the work was to analyze the effectiveness of antiviral therapy (3D mode) in patients with chronic hepatitis C (CHC) GT1 in clinical practice, depending on the presence of comorbid chronic renal insufficiency stage V, who receiving ...
H. V. Venytska, O. V. Riabokon
doaj +1 more source
Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. [PDF]
, 2023 Hepatitis C virus (HCV) infections are more common among US veterans receiving care through Veterans Affairs (VA) Medical Centers than among the general population.
Cheung, Ramsey +13 more
core +1 more source
Kidney International Reports, 2019 Introduction: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-label,
Eric Lawitz +15 more
doaj +1 more source
Use of augmented reality technology for improving visual acuity of individuals with low vision
Indian Journal of Ophthalmology, 2020 Purpose: The objective of this study was to analyze the visual acuity improvement in patients with low vision using augmented reality device who presented to the low vision care (LVC) clinic at a tertiary eye care center.
Sarika Gopalakrishnan +3 more
doaj +1 more source
Kidney International Reports, 2019 Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods: We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1–infected ...
David E. Bernstein +11 more
doaj +1 more source
Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia [PDF]
Vojnosanitetski Pregled, 2019 Background/Aim. The era of direct-acting antiviral (DAA) regimen in the treatment of chronic hepatitis C virus (HCV) started in 2011. The aim of this study was to assess the antiviral efficacy and safety of DAA regimen, ombitasvir (OBV)/paritaprevir (PTV)
Simonović-Babić Jasmina +9 more
doaj +1 more source
Моделювання динаміки ринку криптовалют з використанням інструментів машинного навчання
Sistemnì Doslìdženâ ta Informacìjnì Tehnologìï, 2023 Проаналізовано динаміку кон’юнктури ринку криптовалют (Bitcoin) з використанням інструментарію економетричного оцінювання на основі моделей машинного навчання.
Dmytro Martjanov +2 more
doaj +1 more source
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. [PDF]
PLoS ONE, 2018 ObjectivesThe aim of this multicenter retrospective study was to investigate safety and efficacy of direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coinfection and advanced liver cirrhosis on the liver transplant ...
Julia M Grottenthaler +20 more
doaj +1 more source
Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis [PDF]
International Journal of Medical Arts, 2020 Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations.
Naglaa El-Gendy +3 more
doaj +1 more source
Patterns of olfactory dysfunctions in patients with Parkinson disease
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020 Background Olfactory dysfunction (OD) is a well-established nonmotor manifestations (NMM) of Parkinson disease (PD) which needs objective assessment for better understanding of the disease pathogenesis.
Khaled Hussein Rashed +6 more
doaj +1 more source